Abrdn Life Sciences Investors (HQL)
NYSE: HQL · Real-Time Price · USD
15.87
-0.04 (-0.25%)
Mar 6, 2026, 4:00 PM EST - Market closed
HQL Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
| Other Revenue | 1.94 | 3.98 | 3.02 | 2.29 | 3.39 | |
| Revenue | 1.94 | 3.98 | 3.02 | 2.29 | 3.39 | |
| Revenue Growth (YoY) | -51.30% | 31.83% | 32.05% | -32.59% | 38.97% | |
| Gross Profit | 1.94 | 3.98 | 3.02 | 2.29 | 3.39 | |
| Selling, General & Admin | 5.31 | 5.9 | 6.01 | 6.43 | 5.51 | |
| Operating Expenses | 5.31 | 5.9 | 6.01 | 6.43 | 5.51 | |
| Operating Income | -3.37 | -1.92 | -2.99 | -4.14 | -2.11 | |
| Currency Exchange Gain (Loss) | - | - | 0 | -0.01 | -0.01 | |
| Other Non Operating Income (Expenses) | 0.85 | 0.69 | 1.75 | 2.08 | 0.48 | |
| EBT Excluding Unusual Items | -2.52 | -1.23 | -1.24 | -2.06 | -1.64 | |
| Gain (Loss) on Sale of Investments | 88.11 | 86.53 | -103.37 | 66.59 | 124.7 | |
| Pretax Income | 85.59 | 85.3 | -104.6 | 64.53 | 123.05 | |
| Net Income | 85.59 | 85.3 | -104.6 | 64.53 | 123.05 | |
| Net Income to Common | 85.59 | 85.3 | -104.6 | 64.53 | 123.05 | |
| Net Income Growth | 0.35% | - | - | -47.56% | - | |
| Shares Outstanding (Basic) | 30 | 28 | 26 | 25 | 24 | |
| Shares Outstanding (Diluted) | 30 | 28 | 26 | 25 | 24 | |
| Shares Change (YoY) | 5.48% | 9.28% | 4.10% | 3.29% | 3.03% | |
| EPS (Basic) | 2.89 | 3.04 | -4.07 | 2.62 | 5.15 | |
| EPS (Diluted) | 2.89 | 3.04 | -4.07 | 2.62 | 5.15 | |
| EPS Growth | -4.86% | - | - | -49.23% | - | |
| Dividend Per Share | 1.820 | 1.660 | 1.470 | 1.670 | 1.470 | |
| Dividend Growth | 9.64% | 12.93% | -11.98% | 13.61% | -1.34% | |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | |
| Operating Margin | -174.11% | -48.25% | -99.05% | -181.04% | -62.35% | |
| Profit Margin | 4415.74% | 2143.13% | -3464.88% | 2822.50% | 3628.14% | |
| EBIT | -3.37 | -1.92 | -2.99 | -4.14 | -2.11 | |
| EBIT Margin | -174.11% | -48.25% | -99.05% | -181.04% | -62.35% | |
| Revenue as Reported | 1.94 | 3.98 | 3.02 | 2.29 | 3.39 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.